
Delnova Healthcare LLP
About Delnova Healthcare LLP
Data last updated:
Delnova Healthcare LLP is a limited liability partnership (LLP) based in Thane, Maharashtra, India, recognised as a startup by DPIIT. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 10 October 2017 and has been in existence for over 9 years.
The LLP is registered with the Registrar of Companies (ROC), Mumbai, under LLPIN AAK-8013.
The LLP has a total obligation of contribution of ₹46 Lakh. It is led by designated partners including Vijayendra Kumar Virendrakumar Redasani and Shweta Vijayendrakumar Redasani.
Its latest statement of accounts is for the year ended 31 March 2025. The registered office is at Flat No.103/A – 11 Prakruti Palms Chs Ltd Brahmand Phase 7, Thane, Maharashtra, India – 400607.
As per the financials filed for FY 2023, the LLP reported a revenue of ₹5.74 Cr, a growth of 13% compared to the previous year. For the same year it recorded a net profit of ₹50.52 Lakh (net margin 8.8%) and EBITDA of ₹83.94 Lakh (EBITDA margin 14.6%). Revenue has grown at a compounded annual rate (CAGR) of 33% over three years and 70% over five years.
The LLP has about 25 employees on its provident fund (EPFO) records.
As per MCA filings, the LLP has open charges of ₹1.1 Cr on record.
Delnova Healthcare LLP is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-33-0141601).
Company details
Recognitions & Rankings of Delnova Healthcare
- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-33-0141601
Contact details
Delnova Healthcare LLP's registered office is in Thane, Maharashtra. Its e-mail address is in the company report.
- Email
- Registered AddressFlat No.103/A – 11 Prakruti Palms Chs Ltd Brahmand Phase 7, Thane, Maharashtra, India – 400607
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Delnova Healthcare LLP, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Delnova Healthcare LLP
FY 2025 filings availableDelnova Healthcare LLP reported revenue of ₹5.74 Cr (up 13% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 70% over five years, including 13% growth in the latest year. EBITDA rose 430% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Statement of Account and Solvency | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Income and Expenditure | |||||
| Turnover | |||||
| Other Income | |||||
| Total Income | |||||
| Purchases and Direct Costs | |||||
| Personnel Expenses | |||||
| Administrative Expenses | |||||
| Interest | |||||
| Depreciation | |||||
| Total Expenses | |||||
| Profit Before Tax | |||||
| Tax | |||||
| Profit After Tax | ₹50.52 Lakh | ||||
| Profit Transferred to Partners | |||||
| Assets and Liabilities | |||||
| Partners' Contribution | |||||
| Reserves and Surplus | |||||
| Secured Loans | |||||
| Unsecured Loans | |||||
| Trade Payables | |||||
| Other Liabilities and Provisions | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Loans and Advances | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Statement of Account and Solvency | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| Net Profit Margin | 8.8% | ||||
| Return on Partners' Funds | |||||
| Return on Assets | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Debt to Partners' Funds | |||||
| Interest Coverage | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Turnover Growth | |||||
| Profit Growth | |||||
To see the full financial statements and ratios of Delnova Healthcare LLP, buy the company report.
Designated partners of Delnova Healthcare LLP
Delnova Healthcare has 3 current designated partners and 4 former designated partners. Current designated partners are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vijayendra Kumar Virendrakumar Redasani | Designated Partner | 14 Apr 2021 | 5 Years 6 Months | Current |
| Shweta Vijayendrakumar Redasani | Designated Partner | 10 Oct 2017 | 9 Years 0 Months | Current |
| Minnoli Vijayendrakumar Redasani Also directs: Viracs Healthcare LLP | Designated Partner | 15 Sep 2025 | 1 Years 1 Months | Current |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Mar 2023 | 100711291 | Tata Capital Financial Services Limited | ₹37.76 Lakh | Open | |
| 28 May 2020 | 100348034 | Tata Capital Financial Services Limited | ₹31.62 Lakh | Open | |
| 30 Oct 2019 | 100317112 | Tata Capital Financial Services Limited | ₹40.12 Lakh | Open |
Total charge records: 3 View all charges
Legal cases
No court or tribunal cases involving Delnova Healthcare LLP are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Delnova Healthcare LLP; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Delnova Healthcare LLP has a workforce of 29 employees on its EPFO records as of Mar 29, 2024, across 1 active EPFO establishment.
GST
No GST registration is on our record for Delnova Healthcare LLP; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Delnova Healthcare LLP has 7 designated partner changes on record since 2017: 4 appointments and 3 cessations. The latest: Minnoli Vijayendrakumar Redasani was appointed as Designated Partner on 15 Sep 2025.
1 earlier event is in the company report.
Frequently asked questions
Delnova Healthcare is an active limited liability partnership based in Thane, Maharashtra, India. The LLP works in drug formulation and development, within the pharma industry. It was incorporated on 10 October 2017 (9+ years old) and is registered under LLPIN AAK-8013.
Delnova Healthcare has 3 current designated partners:
- Vijayendra Kumar Virendrakumar Redasani - Designated Partner
- Shweta Vijayendrakumar Redasani - Designated Partner
- Minnoli Vijayendrakumar Redasani - Designated Partner
The latest financial statements of Delnova Healthcare on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 31 March 2025. Year-wise statements from FY 2018 are in the company report.
The LLPIN (Limited Liability Partnership Identification Number) of Delnova Healthcare is AAK-8013. It is issued by the Ministry of Corporate Affairs and uniquely identifies the LLP in India.
Delnova Healthcare was incorporated on 10 October 2017, making it 9+ years old. It is registered with the Registrar of Companies, Mumbai.
Minnoli Vijayendrakumar Redasani was appointed as Designated Partner on 15 Sep 2025. Anjali Ashok Choudhary was appointed as Designated Partner on 14 Apr 2021. Vijayendra Kumar Virendrakumar Redasani was appointed as Designated Partner on 14 Apr 2021. Delnova Healthcare has 7 designated partner changes on record in total.
Yes, Delnova Healthcare is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).
Yes, Delnova Healthcare is registered as a small enterprise under Udyam registration (number: UDYAM-MH-33-0141601).
The registered office of Delnova Healthcare is at Flat No.103A – 11 Prakruti Palms Chs Ltd Brahmand Phase 7, Thane, Maharashtra, India – 400607.
Delnova Healthcare operates in the pharma industry, in the drug formulation and development segment.

